Research programme: proto-oncogene protein c-bcl-2 inhibitors - Oncothyreon is now called Cascadian Therapeutics/Sanford-Burnham Medical Research Institute

Drug Profile

Research programme: proto-oncogene protein c-bcl-2 inhibitors - Oncothyreon is now called Cascadian Therapeutics/Sanford-Burnham Medical Research Institute

Alternative Names: BI-97C1; ONT-701; Sabutoclax

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sanford-Burnham Medical Research Institute
  • Developer Cascadian Therapeutics; Sanford Burnham Prebys Medical Discovery Institute; Virginia Commonwealth University
  • Class Small molecules
  • Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
  • 08 Jun 2016 Oncothyreon is now called Cascadian Therapeutics
  • 12 Sep 2011 Sabutoclax and other small-molecule compounds licensed exclusively to Oncothyreon for the treatment of Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top